1. Home /
    2. Altai Protocol Library /
  2. New Indication: Nivolumab + ipilimumab for first-line unresectable malignant pleural mesothelioma

Altai Protocol Library

1028 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Nivolumab + ipilimumab for first-line unresectable malignant pleural mesothelioma

New Indication: Nivolumab + ipilimumab for first-line unresectable malignant pleural mesothelioma

• Open-label, randomized phase III trial (CheckMate 743)
• Previously untreated unresectable MPM
• Nivolumab + ipilimumab x 2 yrs (n=303) vs. platinum + pemetrexed x 6 cycles (n=302)
• ORR: 40% vs. 43%
• Median DoR: 11.0 mos [8.1-16.5 mos] vs. 6.7 mos [5.3-7.1 mos]
• Median PFS: 6.8 mos vs. 7.2 mos (HR: 1.00 [0.82-1.21])
• Median OS: 18.1 mos vs. 14.1 mos [HR: 0.74 [0.60-0.91])
• Median OS for PD-L1 <1%: 17.3 mos vs. 16.5 mos • Grade 3-4 AEs: Diarrhea (3% vs. 1%), anemia (1% vs. 11%), increased lipase (5% vs. 1%), neutropenia (1% vs. 15%)

Lancet 2021; 397: 375–86.
Pfeiffer P, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
https://doi.org/10.1016/S0140-6736(20)32714-8

Reviewed by Ulas Darda Bayraktar, MD on Feb 6, 2021

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More

Enroll in our newsletter emailing list to receive our newsletter on advances in Hematology Oncology field every three weeks without any delay

    How pleased are you with our library?